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Abstract
Background: Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide
that has been shown to inhibit the growth of human liver cancer cells. In this study, we investigated
the effects of YSL plus doxorubicin on the growth of human hepatocellular carcinoma BEL-7402
cells that had been transplanted into nude mice.
Methods: Nude mice bearing human hepatocellular carcinoma BEL-7402 tumors were treated
with successive intraperitoneal injections of saline; low-, mid-, or high-dose doxorubicin; or low-,
mid-, or high-dose doxorubicin plus YSL. Effects on the weight and volume of the tumors were
evaluated.
Results: Co-administration of YSL and high-dose doxorubicin (6 mg/kg every other day) prolonged
the survival time of tumor-bearing mice as compared to high-dose doxorubicin alone. As well, the
anti-tumor effects of mid- and low-dose doxorubicin (2 and 0.7 mg/kg every other day,
respectively) were enhanced when supplemented with YSL; the tumor growth inhibition rates for
YSL plus doxorubicin were greater than the inhibition rates for the same dosages of doxorubicin
alone. The combination of YSL and doxorubicin decreased chemotherapy-associated weight loss,
leukocyte depression, and heart, liver, and kidney damage as compared to doxorubicin alone.
Conclusion:  The combination of YSL plus doxorubicin enhances the anti-tumor effect and
reduces the side effects associated with doxorubicin chemotherapy.
Background
According to the World Health Organization, 7.6 million
people succumbed to cancer in 2005, accounting for 13%
of all deaths. However, in China, the cancer death rate was
20.2%, and it is expected to reach 23.6% by 2023. Liver
cancer is the third most common cause of death in China
[1].
Anthracene-nucleus antibiotics are anti-tumor drugs that
have been heavily researched and developed for the past
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twenty years. Among those, doxorubicin is the most com-
monly used and the most important; however, its use has
been increasingly limited due to severe associated side
effects, such as myocardial toxicity and bone marrow
depression [2]. Because the dosage of doxorubicin can be
decreased when doxorubicin is given combination with
other anti-tumor drugs, which can also elevate the thera-
peutic effect and relieve side effects of doxorubicin, com-
bination therapy has become a common strategy for
doxorubicin-based chemotherapy.
Tripeptide tyroserleutide (YSL) is a small molecule
polypeptide that consists of three natural amino acids: L-
tyrosine, L-serine, and L-leucine. In our laboratory, we
have observed anti-tumor activity for YSL both in vitro and
in vivo using the MTT method, the mouse model of ascites
fluid-type hepatocarcinoma H22, and the nude mouse
model of human hepatocellular carcinoma [3,4]. In this
study, we established a nude mouse model of human
hepatocellular carcinoma in order to investigate the effect
of YSL on tumor growth when given in combination with
doxorubicin.
Methods
Cell culture
Human hepatocellular carcinoma BEL-7402 cells were
purchased from Institute of Cell Biology, Shanghai,
Academia Sinica. The cells were cultured in RPMI 1640
supplemented with 10% fetal bovine serum in a humidi-
fied atmosphere of 5% CO2 at 37°C. During cultivation,
BEL-7402 cells remained free of mycoplasma or bacterial
contamination.
Animals
Healthy female BALB/c (nu/nu) mice (4–5 weeks old, 18–
22 g) were obtained from Chinese Academy of Medical
Sciences (Beijing, China). The animals were housed at our
university under specific pathogen-free conditions accord-
ing to the guidelines of the Chinese Association for Labo-
ratory Animal Care, using a laminar airflow rack. Animals
had continuous access to sterilized food pellets and auto-
claved water, and a 12-hr light/dark cycle. The tempera-
ture was maintained at 22–26°C and 50–70% relative
humidity. All studies were performed according to the reg-
ulations of Tianjin Medical University experimental ani-
mal center and obtained the ethical approval from Tianjin
Council for the Care of Animal in Medical Research.
Nude mouse model of human hepatocellular carcinoma 
[5]
To establish the human hepatocellular carcinoma model,
BEL-7402 cells in exponential phase were grown to a den-
sity of 1 × 108/ml. 0.1 ml of the cell suspension was
injected subcutaneously into the right back of every nude
mouse. Mice with tumors of uniform volume were
selected and randomly divided into different treatment
groups when the tumor volume reached 100 mm3.
YSL plus high-dose doxorubicin combination therapy
YSL was obtained from Shenzhen Kangzhe Pharmaceuti-
cal, China. Doxorubicin (Adriamycin, ADM) was
obtained from Zhejiang Haizheng Pharmaceutical Co.,
Ltd.
Nude mice bearing tumors were randomly divided into
high-dose doxorubicin (6 mg/kg every other day), YSL
(320 μg/kg/d), YSL (320 μg/kg/d) plus high-dose doxoru-
bicin (6 mg/kg every other day), and saline (0.2 ml/d)
groups; each group had twenty mice. All medicines were
dissolved in 0.2 ml saline. Doxorubicin was administered
intraperitoneally (IP) every other day, YSL and saline
(control) were administered every day. For animals receiv-
ing combination therapy, the two medications were
administered at a 4-hr interval. Mice received successive IP
administrations for 30 days or until the death of mouse.
Beginning on the day after the first administration, we
observed activity, stool color and stool patterns of the
mice in all treatment groups. We recorded the survival sta-
tus of mice daily and calculated the rate of life extension
according to the following formula: the rate of life exten-
sion = (average survival days of experiment group-average
survival days of control group)/average survival days of
control group × 100%.
YSL plus mid-dose doxorubicin combination therapy
Nude mice bearing tumors were randomly divided into
mid-dose doxorubicin (2 mg/kg every other day), YSL
(320 μg/kg/d), YSL (320 μg/kg/d) plus mid-dose doxoru-
bicin (2 mg/kg every other day), and saline (0.2 ml/d)
groups; each group had twelve mice. Mice received IP
administrations for 30 successive days. The weights of
mice were measured every three days until the experiment
was terminated.
On the day after treatment termination, blood samples
were obtained from the angular vein and anticoagulated
with heparin. We measured hemoglobin levels, blood
platelets count, and leukocyte counts. Hearts, livers, and
kidneys were fixed immediately in 10% formalin. Paraf-
fin-embedded sections of each tissue sample were stained
with hematoxylin and eosin (HE). The weight and three
perpendicular diameters of every tumor were recorded.
Tumor volume was calculated by the following formula: V
= (1/6) π ABC, where V is the tumor volume, and A, B, and
C are the three tumor diameters. The rate of tumor inhibi-
tion = (average tumor weight of control group – average
tumor weight of experiment group)/average tumor weight
of control group × 100%.BMC Cancer 2008, 8:342 http://www.biomedcentral.com/1471-2407/8/342
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YSL plus low-dose doxorubicin
Nude mice bearing tumors were randomly divided into
low-dose doxorubicin (0.7 mg/kg every other day), YSL
(320 μg/kg/d), YSL (320 μg/kg/d) plus low-dose doxoru-
bicin (0.7 mg/kg every other day), and saline (0.2 ml/d)
groups; each group had twelve mice. Treatments were
administered IP for 60 successive days. Mouse characteris-
tics including body weights, blood counts, and tumor vol-
umes and weights were observed and recorded as
described in the study of mid-dose doxorubicin.
Statistical Analysis
Data are expressed as mean ± standard deviation (SD).
Statistical significances of survival time differences were
analyzed according to the Kaplan-Meier method using
SPSS software. The statistical significance of other differ-
ences was tested using one-way analysis of variance
(ANOVA) followed by the Student-Newman-Keuls test.
Statistical significance was set at P < 0.05.
Results
YSL plus high-dose doxorubicin prolongs the survival time 
of nude mice bearing tumors compared with doxorubicin 
alone
After about 10 days of administration, the mice that
received high-dose doxorubicin alone showed weight loss
and decreased activity level. Similar changes were
observed in the YSL plus doxorubicin group; however, in
general, the condition of the combination group was bet-
ter than that of the doxorubicin group. No obvious side
effects were observed in YSL group.
All the animals in YSL group and saline group were still
alive 30 days later (termination of the experiments). The
mean survival time of mice that received YSL plus high-
dose doxorubicin was longer than that of mice that
received high-dose doxorubicin alone. This difference was
significant, and the extension rate of survival time was
16.67% (P < 0.05; Figure 1).
Co-administration of YSL diminishes the side effects 
associated with mid-dose doxorubicin
After about 12 days, the mice treated with mid-dose dox-
orubicin alone showed decreased body temperature and
lackluster hair. Similar changes were observed in the YSL
combination group, but in general, their condition was
better than that of the doxorubicin group. The body tem-
perature of the mice that received YSL and doxorubicin
was lower than that of the mice that received doxorubicin
alone. Mice in YSL group and saline group were in good
physical condition and showed weight gain. There were
no significant difference in weight gain between YSL
group and saline group. The weight of the mice in YSL
plus mid-dose doxorubicin and mid-dose doxorubicin
alone was lower after drug administration than before
administration. However, the mean weight of the YSL
combination group was higher than the mean weight of
the doxorubicin group, and the mean weight loss for YSL
combination group was lower than that of the doxoru-
bicin group. As well, the weight loss in YSL combination
group manifested later than in the doxorubicin group
(Figure 2).
There were no significant difference in hemoglobin levels,
blood platelets count and between YSL group and saline
group. Leukocyte counts were markedly lower in the dox-
orubicin group than in the YSL combination group and
YSL alone group, and were significantly lower as com-
pared to the saline group (P < 0.05). Blood platelet counts
were higher in doxorubicin group than in both the YSL
combination and saline groups, but there was no statisti-
cal significance versus the saline group (P > 0.05). Hemo-
globin levels in both the doxorubicin and YSL
combination groups were higher than in the saline group,
but these differences were not statistically significant (Fig-
ure 3).
Including YSL in the treatment regimen decreased the
toxic effects of mid-dose doxorubicin on the heart, liver,
and kidney of nude mice bearing tumors as shown by HE
staining (Figure 4). In the mid-dose doxorubicin group,
there was puffing of cardiac muscle cells, enhanced acido-
philia, and augmented interspaces. The presence of these
pathological changes was softened in the YSL combina-
tion group, in which the structure of heart muscle was
comparatively complete. The structure of hepatic lobules
was not clear in the mid-dose doxorubicin group, and
there was enhanced acidophilia and interstitial edema.
However, in the YSL combination group the structure of
the hepatic lobules was clear. The structure of the kidney
cortical labyrinth and medullary ray was acceptable in the
mid-dose doxorubicin group, but the cell proliferation of
the glomeruli decreased, there was party acinus renalis
blood capillary glomus congestion, narrowed Bowman's
space, and interstitial congestion. These effects were
muted slightly in the YSL combination group. There are
no obvious pathological changes in YSL alone and saline
group.
YSL alone and mid-dose doxorubicin could inhibit tumor
growth in nude mice bearing human hepatocellular carci-
noma BEL-7402 tumors. The tumor inhibition rate was
34.39% and 53.35%, respectively, which were statistically
significant as compared with the saline group (P < 0.05).
The tumor inhibition rate for combination therapy was
56.15%, which was statistically significant as compared to
the saline group (P < 0.05). However, there was no signif-
icance difference between the inhibition rates of the YSL
combination group and the doxorubicin group (P > 0.05;
Figure 5).BMC Cancer 2008, 8:342 http://www.biomedcentral.com/1471-2407/8/342
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The anti-tumor effects of YSL plus low-dose doxorubicin
Mice in four groups, including YSL group, YSL plus low-
dose doxorubicin group, low-dose doxorubicin group and
saline group, were in good physical condition and
showed weight gain. Mice treated with YSL group or low-
dose doxorubicin (0.7 mg/kg every other day) or YSL plus
low-dose doxorubicin tolerated therapy well, there were
no overt side effects in either group. The mean body
weight of nude mice in the YSL combination group was
higher than that in doxorubicin group, but this difference
was not significant (P > 0.05; Figure 6).
There were no obvious differences in white blood cell
counts, platelet counts, or hemoglobin levels among the
three treatment groups, and there were no significance dif-
ferences as compared to the saline group (P > 0.05; Figure
7).
The groups treated with low-dose doxorubicin were
observed for 60 successive days. The tumor inhibition rate
of YSL alone group and YSL combination group were
37.11% and 52.17%, respectively, higher than that of the
low-dose doxorubicin group (30.14%). The tumor inhibi-
tion rate of the YSL combination group was significantly
Survival times of nude mice bearing human hepatocellular carcinoma BEL-7402 tumors treated with either high-dose doxoru- bicin or YSL plus high-dose doxorubicin Figure 1
Survival times of nude mice bearing human hepatocellular carcinoma BEL-7402 tumors treated with either 
high-dose doxorubicin or YSL plus high-dose doxorubicin. BEL-7402 cell suspension (1 × 107/each mouse) was subcu-
taneously inoculated into the right back of every nude mouse. When tumor volume research 100 mm3, they were randomly 
divided into different groups (n = 20). The mice were administrated i.p. for 30 days or until the death of mouse. Statistical sig-
nificances of survival time were tested by Kaplan-Meier method using SPSS, and difference between the group of high dosage of 
ADM and the group of YSL combination group was tested by Log Rank, statistical significance was set at P < 0.05. ADM, doxo-
rubicin or adriamycin; YSL, tripeptide tyroserleutide.BMC Cancer 2008, 8:342 http://www.biomedcentral.com/1471-2407/8/342
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different as compared to the saline group (P < 0.05), but
not as compared to the doxorubicin group (P > 0.05; Fig-
ure 8).
Discussion
Doxorubicin is a broad-spectrum antibiotic used widely
for its anti-tumor activity. It is considered one of the most
useful anti-tumor drugs available [6]. However, it's clini-
cal use is limited by its serious side effects including bone
marrow depression [7], liver and kidney injury [8,9], and
cardiac toxicity [10]. Cardiac toxicity is considered the
main side effect; some consider doxorubicin's dose-
dependent cardiac toxicity to be more dangerous than its
other serious side effects [11]. When doxorubicin is com-
bined with other chemotherapeutic agents such as cyclo-
phosphamide, bleomycin, and cisplatin, doxorubicin's
cardiac toxicity is amplified. Therefore, doxorubicin dos-
age cannot be escalated and its use in combination ther-
apy is limited. Identifying an acceptable therapeutic
partner for doxorubicin remains an area of considerable
clinical interest.
YSL is novel anti-tumor peptide that can inhibit the
growth of human hepatocellular carcinoma cells without
observable side effects. High performance and low toxicity
are characteristic of YSL, and have become the basis efforts
to use YSL and doxorubicin combination therapy to cure
hepatoma. In this study, we imitated the clinical condi-
tions of doxorubicin therapy and examined the therapeu-
tic efficacy of YSL in combination with different dosages
of doxorubicin. We evaluated the effects on the survival in
a nude mouse model of human hepatocellular carcinoma.
Changes in tumor volume and weight are the most direct
indices for judging the efficacy of anti-tumor therapy. We
found that the tumor inhibition rate was enhanced when
YSL was combined with mid- or low-dose doxorubicin,
demonstrating that YSL enhances the anti-tumor effect of
The effects of YSL plus mid-dose doxorubicin on the weight of nude mice bearing human hepatocellular carcinoma BEL-7402  tumors Figure 2
The effects of YSL plus mid-dose doxorubicin on the weight of nude mice bearing human hepatocellular carci-
noma BEL-7402 tumors. BEL-7402 cell (1 × 107/every mouse) was subcutaneously inoculated into the right back of every 
nude mouse. When the tumors had reached an average volume of 100 mm3, the tumor-bearing nude mice were randomly 
divided into different groups (n = 12). Drugs delivered by i.p. injection for 30 days successively. We weighted every group mice 
by electronic balance every 3 day and recorded the weight. Data points represent mean body weight ± SD. ADM, doxorubicin 
or adriamycin; YSL, tripeptide tyroserleutide.BMC Cancer 2008, 8:342 http://www.biomedcentral.com/1471-2407/8/342
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doxorubicin. In particular, the tumor inhibition rate of
YSL plus low-dose doxorubicin was higher than that of the
doxorubicin alone, whereas there was no statistically sig-
nificant difference between the doxorubicin and saline
groups. The manifestation of therapeutic action when
low-dose doxorubicin is given in conjunction with YSL
versus no therapeutic action when given alone suggests
that YSL synergizes with doxorubicin. The inclusion of
YSL can reduce the dosage required to obtain the clinical
benefit of doxorubicin while limiting the potential side
effects. These data are consistent with the principle of
combined therapy for tumor treatment [12].
Other key indices for evaluating tumor therapy efficacy
are survival time and survival quality. Research about sur-
vival quality has received increasing attention in the inter-
national community in recent years. Survival quality
(quality-of-Life, QOL) has been widely used as an index to
evaluate therapeutic results [13,14]. At the 2005 meeting
of the American Society of Clinical Oncology (ASCO),
more than 98 articles about survival quality were pre-
sented. The completely new indexes-elevate survival qual-
ity and prolong survival time on tumor therapy curative
effect was introduced clearly at ASCO 2007. In clinical
anti-tumor therapy, elevating patient survival quality
includes malignant tumor rehabilitation care [15], pallia-
tive treatment [16], and attenuation and synergy of radio-
therapy and chemotherapy [17].
One focus of our research is on the attenuation and syner-
gistic effects of YSL in combination chemotherapy, and
the superiority of YSL for treating hepatoma. We first
observed the attenuating effects of YSL in combination
with deadly dosages of doxorubicin. High dosages of dox-
orubicin (6 mg/kg every other day) can induce death in
mice; however, adding YSL to high-dose doxorubicin sig-
nificantly prolongs the survival time of nude mice bearing
tumors as compared to doxorubicin alone. These data
suggest that YSL enhances nude mice's tolerance to doxo-
rubicin, thereby increasing doxorubicin's clinical value.
The effects of YSL plus mid-dose doxorubicin on the hematological indices of nude mice bearing human hepatocellular carci- noma BEL-7402 tumors Figure 3
The effects of YSL plus mid-dose doxorubicin on the hematological indices of nude mice bearing human hepa-
tocellular carcinoma BEL-7402 tumors. BEL-7402 cell (1 × 107/every mouse) was subcutaneously inoculated into the 
right back of every nude mouse. When the tumors had reached an average volume of 100 mm3, the tumor-bearing nude mice 
were randomly divided into different groups (n = 12). Drugs delivered by i.p. injection for 30 days successively. At the next day 
of the last administration, blood was obtained from angular vein of nude mice, then blood was anticoagulated by heparin, we 
detected hematoglobin level and counted PLT and WBC. All data were analyzed by one-way analysis of variance using SPSS. 
The difference between two groups was analyzed by the Student-Newman-Keuls test. Standard deviation was represented by 
error line. *P < 0.05 as compared to the saline group. ADM, doxorubicin or adriamycin; YSL, tripeptide tyroserleutide. WBC, 
white blood cells; PLT, platelets; Hb, hemoglobin.BMC Cancer 2008, 8:342 http://www.biomedcentral.com/1471-2407/8/342
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The effects of YSL plus mid-dose doxorubicin on the internal organs of nude mice bearing human hepatocellular carcinoma  BEL-7402 tumors Figure 4 (see previous page)
The effects of YSL plus mid-dose doxorubicin on the internal organs of nude mice bearing human hepatocellu-
lar carcinoma BEL-7402 tumors. BEL-7402 cell (1 × 107/every mouse) was subcutaneously inoculated into the right back 
of every nude mouse. When the tumors had reached an average volume of 100 mm3, the tumor-bearing nude mice were ran-
domly divided into different groups (n = 12). The mice were administrated i.p. 30 days. At the next day of the last administra-
tion, nude mice were sacrificed, and then put the heart, liver and kidney tissue into 10% formalin to fix and paraffin-embedded 
sections of each tissue sample were stained routinely with hematoxylin and eosin (HE). Figures 4A, 4B, 4C and 4D are heart 
samples. Figures 4E, 4F, 4G, and 4H are liver samples. Figures 4I, 4J, 4K and 4L are kidney samples. Figure 4A (Mid-dose doxo-
rubicin): Myocardial cells are pultaceous and characterized by enhanced acidophilia. Figure 4B (YSL plus mid-dose doxorubicin): 
The transverse striation of myocardial cells is clear and with good repair. Figure 4C (YSL group) and Figure 4D (Saline group): 
There are no obvious abnormalities. Figure 4E (Mid-dose doxorubicin): There was enhanced acidophilia and interstitial edema. 
Figure 4F (YSL plus mid-dose doxorubicin): The structure of hepatic lobules is clear. Figure 4G (YSL group) and Figure 4H 
(Saline group): There are no obvious abnormalities. Figure 4I (Mid-dose doxorubicin): There are congestion of renal glomeruli 
and narrowed Bowman's space. Figure 4J (YSL plus mid-dose doxorubicin): Nephric tubules exhibit swelling. Figure 4K (YSL 
group) and Figure 4L (Saline group): There are no obvious abnormalities.
The effects of YSL plus mid-dose doxorubicin on tumor growth in nude mice bearing human hepatocellular carcinoma BEL- 7402 tumors Figure 5
The effects of YSL plus mid-dose doxorubicin on tumor growth in nude mice bearing human hepatocellular 
carcinoma BEL-7402 tumors. BEL-7402 cell (1 × 107/every mouse) was subcutaneously inoculated into the right back of 
every nude mouse. When the tumors had reached an average volume of 100 mm3, the tumor-bearing nude mice were ran-
domly divided into different groups (n = 12). The mice were administrated i.p. 30 days. At the next day of the last administra-
tion, tumor tissue were stripped and three diameter which were vertical each other were measured. The tumor volume was 
calculated by V (cm3) = (1/6) π ABC, and A, B, C was three diameter of tumor. Then we weigh the tumor and calculated the 
tumor inhibition rate by tumor inhibition rate= (average weight of control group-average weight of experimental group)/aver-
age weight of control group × 100%. All data were analyzed by one-way analysis of variance using SPSS. The difference between 
two groups was analyzed by the Student-Newman-Keuls test. Standard deviation was represented by error line. *P < 0.05 as 
compared to the saline group. ADM, doxorubicin or adriamycin; YSL, tripeptide tyroserleutide.BMC Cancer 2008, 8:342 http://www.biomedcentral.com/1471-2407/8/342
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YSL in combination with mid-dose doxorubicin improves
the survival status of nude mice bearing tumors and
decreases doxorubicin-associated side effects such as
weight loss, decreased body temperature, and reduced
activity level. These data suggest that YSL plus doxorubicin
both prolongs the survival time of nude mice bearing
tumor and enhances their survival quality, which has
important clinical implications.
Bone marrow depression is a common side effect of dox-
orubicin, and the influence on leukocyte counts is the
most obvious. About 60–80% of patients have leukocyte
depression after 10–15 days of doxorubicin therapy, and
they recover by about day 21 of therapy [18]. YSL has
strong protective effect on doxorubicin-induced leukocyte
depression. In this study, YSL given in combination with
mid-dose doxorubicin increased the number of leuko-
cytes; thus, the inclusion of YSL in doxorubicin treatment
regimens could reduce rate of infectious complications.
During therapy, doxorubicin can induce fatal cardiac tox-
icity, and doxorubicin-induced liver and kidney injury can
be life threatening. Mid-dose doxorubicin can injure the
heart, liver, and kidneys to varying degrees. We found that
the degree of injury was reduced in the YSL combination
group as compared to the doxorubicin group; that is, YSL
seemed to prevent or repair doxorubicin-induced heart,
liver, and kidney injury. The cardio- and hepatoprotective
effects of YSL were especially obvious. In the YSL combi-
nation group the structure of cardiocyte was clear, hepatic
lobules was complete, and the structure of the kidney cor-
tical labyrinth and medullary ray was clear compared to
the doxorubicin group.
The elevated doxorubicin levels in the blood conduce to
reaching a high concentration in tumor tissue to increase
the anti-tumor effects of doxorubicin [19]. However,
some organs with abundant blood supply such as heart,
liver and kidney will be damaged because of high doxoru-
bicin concentration. In this study, we found that high-
and mid-dose doxorubicin had obvious anti-tumor effects
on human hepatocellular carcinoma BEL-7402 cells, but
doxorubicin also influenced the common status and basic
vital signs of nude mice bearing tumors severely. Doxoru-
bicin's side effects include hypo-leukocytosis, cardiac
injury, liver and kidney toxicity, weight loss, and survival
time decurtation. Compared with control group, low-
dose doxorubicin induced less severe side effects, but had
no significant inhibition on the growth of human hepato-
cellular carcinoma BEL-7402 cells in nude mice. Combi-
nation therapy with YSL significantly protected the mice
from doxorubicin-induced side effects and increased the
The effects of YSL plus low-dose doxorubicin on the body weight of nude mice bearing human hepatocellular carcinoma BEL- 7402 tumors Figure 6
The effects of YSL plus low-dose doxorubicin on the body weight of nude mice bearing human hepatocellular 
carcinoma BEL-7402 tumors. BEL-7402 cell (1 × 107/every mouse) was subcutaneously inoculated into the right back of 
every nude mouse. When the tumors had reached an average volume of 100 mm3, the tumor-bearing nude mice were ran-
domly divided into different groups (n = 12). The mice were administrated i.p. 60 days. The body weights were weighing by 
electronic balance every three day. Standard deviation was represented by error line. ADM, doxorubicin or adriamycin; YSL, 
tripeptide tyroserleutide.BMC Cancer 2008, 8:342 http://www.biomedcentral.com/1471-2407/8/342
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anti-tumor effects of doxorubicin. YSL could induce the
apoptosis of human hepatocellular carcinoma BEL-7402
cells [20]. And Xu et al found that tumor necrosis factor-
related apoptosis inducing ligand (TRAIL) could signifi-
cantly increase the anti-tumor effects of doxorubicin
through inducing the apoptosis of cancer cells [21]. So we
think that the mechanisms enabling YSL to augment the
cytotoxicity of doxorubicin may correlate well with the
increased ability of doxorubicin when combined with YSL
to induce apoptosis. Also YSL significantly increased the
expression of PTEN in human hepatocellular carcinoma
BEL-7402 cell. Over-expression of PTEN could increase
the sensitivity to doxorubicin in human breast cancer
MCF-7 cells [22]. The boosting of activity of doxorubicin
when combined with YSL may result from the increased
expression of PTEN to increase the sensitivity of BEL-7402
cells to doxorubicin.
In addition, our study observed the effects of co-adminis-
tration of YSL and high-, mid-, and low-dose doxorubicin
on nude mice bearing tumors. Although few side effects
were recorded in low-dose doxorubicin group, there was
no significant difference in tumor volumes and weights
between the low-dose doxorubicin group and saline
group. The tumor inhibition rate of YSL combination
group was higher than that of the low-dose doxorubicin
group, significantly different as compared to the saline
group. YSL might enhance the efficacy of doxorubicin and
have a dosage sparing effect which can reduce the dosage
of doxorubicin to reduce its side-effects. Hence, it is possi-
ble that YSL can act as a new anti-tumor drug for the clin-
ical development of combination with doxorubicin. Also
YSL could reduce doxorubicin-induced side effects in
combination with mid- and high-dose doxorubicin which
produced significant anti-tumor effects. For example YSL
prolonged the survival time of nude mice bearing tumor
The effects of YSL combination with low dosage of doxorubicin on hematological indices of nude mice bearing human hepato- cellular carcinoma BEL-7402 tumors Figure 7
The effects of YSL combination with low dosage of doxorubicin on hematological indices of nude mice bearing 
human hepatocellular carcinoma BEL-7402 tumors. BEL-7402 cell (1 × 107/every mouse) was subcutaneously inocu-
lated into the right back of every nude mouse. When the tumors had reached an average volume of 100 mm3, the tumor-bear-
ing nude mice were randomly divided into different groups (n = 12). Drugs delivered by i.p. injection for 60 days successively. 
At the next day of the last administration, blood was obtained from angular vein of nude mice, then blood was anticoagulated 
by heparin, we detected hematoglobin level and counted PLT and WBC. All data were analyzed by one-way analysis of variance 
using SPSS. The difference between two groups was analyzed by the Student-Newman-Keuls test. Standard deviation was rep-
resented by error line. Statistical significance was set at P < 0.05. ADM, doxorubicin or adriamycin; YSL, tripeptide tyroserleu-
tide. WBC, white blood cells; PLT, platelets; Hb, hemoglobin.BMC Cancer 2008, 8:342 http://www.biomedcentral.com/1471-2407/8/342
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and overcame the negative side effects of doxorubicin by
protecting hematological and vital organ health. Doxoru-
bicin can undergo redox cycling to produce reactive oxy-
gen species. The oxidant-generating activity of
doxorubicin is thought to be responsible for the side
effects of the drug [23]. Further research needs to be car-
ried out to test whether YSL would interfere with oxidant-
generating activity of doxorubicin to inhibit side effects of
drug. Moreover, the mechanism accounting for side-
effects of doxorubicin mainly depends on its cytotoxicity.
Further experiment is required to show that YSL could
selectively induce apoptosis of human hepatocellular car-
cinoma cells but not normal cells from various organs.
Conclusion
In this study, the potential attenuation and synergistic
effect of tripeptide tyroserleutide plus doxorubicin against
human hepatocellular carcinoma in nude mice were
investigated. Co-administration of YSL and low-, mid-, or
high-dose doxorubicin respectively decreased chemother-
apy-associated weight loss, leukocyte depression, and
heart, liver, and kidney damage as compared to doxoru-
bicin alone. Although there were no statistically signifi-
cant differences in tumor weights between doxorubicin
alone group and YSL plus doxorubicin group, YSL plus
doxorubicin produced greater tumor inhibition rate than
doxorubicin. The combination of YSL plus doxorubicin
increased the sensitivity of tumors to chemotherapeutic
drugs and reduces the side effects associated with doxoru-
bicin chemotherapy.
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